Dr. Gorman Discusses FDA Approval of New Breast Cancer Medications

Waxahachie, Texas -

Dr. Valerie Gorman, a breast cancer surgeon in Waxahachie, Texas. She recently released an article discussing the FDA’s accelerated approval of two new breast cancer medications, Todelvy and Tukysa. These two drugs were able to be advanced through the approval process in an accelerated rated due to the current COVID-19 pandemic, though each must be taken under specific conditions. Testing on these medications will continue so that clinical data can continue to be gathered before full approval can be met.

Dr. Gorman took the time to explain each medication’s function, what it targets, and what it has been shown to effect. She also explains the common side effects of these drugs for anyone who may take them.

Tukysa is intended for patients with metastatic, HER2-positive breast cancers. It can only be given on the condition that at least one other “anti-HER2-based treatment geared towards metastasis” has already been attempted. While further clinical trials are being attempted, Tukysa has been granted accelerated approval to help those with advanced cases of such an extreme form of cancer.

Trodelvy targets metastatic breast cancers and, in previous trials, had a “response rate [of] 33%, and 55.6% of those responders maintained their response at least six months”. This medication can be taken on the condition that at least two treatments have been previously pursued for their metastatic cancer.

Dr. Gorman is board certified by the American Board of Surgery and serves as both the Medical Director of Surgical Services and Chief of Surgery at Baylor Scott & White Medical Center in Waxahachie. Her goal is to keep her patients informed and to always offer her patients an informed, personalized approach to breast cancer treatment.